• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . miRNA biomarkers for prognosis and therapy monitoring in a multi-ethnic cohort with SARS-CoV-2 infection

tetano

Editor, Senior Moderator
Sci Rep


. 2025 Aug 21;15(1):30815.
doi: 10.1038/s41598-025-15248-6. miRNA biomarkers for prognosis and therapy monitoring in a multi-ethnic cohort with SARS-CoV-2 infection

Farah Mustafa[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Waqar Ahmad[SUP] #[/SUP][SUP] 4 [/SUP], Bushra Gull[SUP] 4 [/SUP], Jasmin Baby[SUP] 4 [/SUP], Neena G Panicker[SUP] 4 [/SUP], Thanumol Abdul Khader[SUP] 4 [/SUP], Hala Abdul Baki[SUP] 4 [/SUP], Erum Rehman[SUP] 5 [/SUP], Asif M Salim[SUP] 5 [/SUP], Rubina L G Ahmed[SUP] 6 [/SUP], Hamda H Khansaheb[SUP] 7 8 [/SUP], Maya Habous[SUP] 5 [/SUP], Laila M J A AlDabal[SUP] 5 [/SUP], Soumeya Jaballah[SUP] 4 9 [/SUP], Saif S Alqassim[SUP] 7 [/SUP], Alawi Alsheikh-Ali[SUP] 7 8 [/SUP], Tahir A Rizvi[SUP] 10 11 12 [/SUP]



Affiliations
Abstract

This study aimed to identify miRNA-based biomarkers in a multi-ethnic cohort of SARS-CoV-2-infected individuals to enhance preparedness for future variants of concern. A total of 31 healthy controls and 154 infected patients were enrolled, from which 13 matched controls and 38 infected nasal swab samples were analyzed using miRNA sequencing, followed by qRT-PCR validation. Among the 1788 miRNAs detected, 14 differentially expressed miRNAs and four novel miRNAs were identified, with novel-miR-264-5p showing a ≥ 2-fold change. Correlation with clinical markers highlighted several miRNAs as potential prognostic biomarkers. Seven miRNAs, including miR-146b-3p, miR-154-5p, miR-5010-3p, miR-127-3p, miR-335-3p, miR-30c-5p, and miR-202-5p, showed strong prognostic potential. Combined ROC analysis demonstrated that a panel of top-performing miRNAs significantly enhanced diagnostic accuracy (AUC 0.939-0.972; p < 0.0001). Moreover, integrating miRNA biomarkers with clinical parameters further improved performance (AUC = 0.982; p < 0.0001). miR-146b-3p, detected exclusively in infected patients, emerged as a highly specific biomarker. Several nasal miRNAs mirrored blood profiles, highlighting the utility of nasal swabs for non-invasive monitoring. Collectively, these findings suggest that miRNA-based biomarkers, alone or combined with clinical markers, offer a promising platform for COVID-19 prognosis and diagnosis, and lay groundwork for future miRNA-based antiviral strategies.

Keywords: Biomarkers; COVID-19; Infectious diseases; MiRNAs; MiRNAseq; Nasopharyngeal swabs; Respiratory diseases; SARS-CoV-2; Variants-of-Concern (VOC).

 
Back
Top Bottom